Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.74 |
| ▸ | HTR2C | P28335 | 2/20 | 0.74 |
| ▸ | HTR2B | P41595 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970860 | 1.00 | HTR2A (0.74) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970941 | 0.91 | HTR2A (0.59) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970865 | 0.88 | HTR2A (0.60) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL29543975 | 0.88 | HTR2A (0.71) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970922 | 0.88 | HTR2A (0.71) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL23360647 | 0.87 | HTR2A (0.72) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL29967870 | 0.87 | HTR2A (0.72) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL1119068 | 0.86 | HTR2A (1.00) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970970 | 0.83 | HTR2A (0.93) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970881 | 0.80 | HTR2A (0.81) | HTR2AHTR2CHTR2BKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4452986-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118055766-A | Magic and non-magic serotonin receptor agonist and its preparing process and usage | 库莱恩有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023225043-A1 | TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4251139-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251181-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR2C 2/4885HTR2B 7/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR2C 2/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.